 Humanigen Inc NASDAQ: HGEN has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19. Data suggested that Black and African-American patients having a CRP over 150 mgL may be the highest responders to treatment, with a nearly 9-fold increase in the likelihood of survival without ventilation SWOV. 